skip to main content
Idioma:
Mostrar Somente
Refinado por: assunto: Life Sciences & Biomedicine remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

Ribas, Antoni ; Lawrence, Donald ; Atkinson, Victoria ; Agarwal, Sachin ; Miller, Jr, Wilson H ; Carlino, Matteo S ; Fisher, Rosalie ; Long, Georgina V ; Hodi, F Stephen ; Tsoi, Jennifer ; Grasso, Catherine S ; Mookerjee, Bijoyesh ; Zhao, Qing ; Ghori, Razi ; Moreno, Blanca Homet ; Ibrahim, Nageatte ; Hamid, Omid

Nature medicine, 2019-06, Vol.25 (6), p.936-940 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por
2
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, Paolo Antonio ; Ferrucci, Pier Francesco ; Fisher, Rosalie ; Del Vecchio, Michele ; Atkinson, Victoria ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Long, Georgina V ; Di Giacomo, Anna Maria ; Svane, Inge Marie ; Lotem, Michal ; Bar-Sela, Gil ; Couture, Felix ; Mookerjee, Bijoyesh ; Ghori, Razi ; Ibrahim, Nageatte ; Moreno, Blanca Homet ; Ribas, Antoni

Nature medicine, 2019-06, Vol.25 (6), p.941-946 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por
3
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Ferrucci, Pier Francesco ; Di Giacomo, Anna Maria ; Del Vecchio, Michele ; Atkinson, Victoria ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Long, Georgina V ; Stephens, Rosalie ; Svane, Inge Marie ; Lotem, Michal ; Abu-Amna, Mahmoud ; Gasal, Eduard ; Ghori, Razi ; Diede, Scott J ; Croydon, Elizabeth S ; Ribas, Antoni ; Ascierto, Paolo Antonio

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001806 [Periódico revisado por pares]

England: BMJ Publishing Group Ltd

Texto completo disponível

Citações Citado por
4
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Marabelle, Aurelien ; Le, Dung T ; Ascierto, Paolo A ; Di Giacomo, Anna Maria ; De Jesus-Acosta, Ana ; Delord, Jean-Pierre ; Geva, Ravit ; Gottfried, Maya ; Penel, Nicolas ; Hansen, Aaron R ; Piha-Paul, Sarina A ; Doi, Toshihiko ; Gao, Bo ; Chung, Hyun Cheol ; Lopez-Martin, Jose ; Bang, Yung-Jue ; Frommer, Ronnie Shapira ; Shah, Manisha ; Ghori, Razi ; Joe, Andrew K ; Pruitt, Scott K ; Diaz, Jr, Luis A

Journal of clinical oncology, 2020-01, Vol.38 (1), p.1-10 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
5
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study

Moreau, Philippe ; Ghori, Razi ; Farooqui, Mohammed ; Marinello, Patricia ; San Miguel, Jesus

British journal of haematology, 2021-07, Vol.194 (1), p.e48-e51 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
6
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, Maria‐Victoria ; Orlowski, Robert Z. ; Ocio, Enrique M. ; Rodríguez‐Otero, Paula ; Reece, Donna ; Moreau, Philippe ; Munshi, Nikhil ; Avigan, David E. ; Siegel, David S. ; Ghori, Razi ; Farooqui, Mohammed Z. H. ; Marinello, Patricia ; San-Miguel, Jesus

British journal of haematology, 2019-09, Vol.186 (5), p.e117-e121 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, Saad Zafar ; Schjesvold, Fredrik ; Oriol, Albert ; Karlin, Lionel ; Cavo, Michele ; LeBlanc, Richard ; Takezako, Naoki ; Lim, Andrew Boon Ming ; Suzuki, Kenshi ; Kosugi, Hiroshi ; Grigoriadis, George ; Avivi, Irit ; Facon, Thierry ; Jagannath, Sundar ; Lonial, Sagar ; Ghori, Razi Uddin ; Farooqui, Mohammed Z H ; Marinello, Patricia ; Lim, Andrew ; Grigoriadis, George ; Walker, Trish ; Nicol, Andrew ; LeBlanc, Richard ; Reece, Donna ; Elemary, Mohamed ; Karlin, Lionel ; Attal, Michel ; Engelhardt, Monika ; Mackensen, Andreas ; Quinn, John ; Avivi, Irit ; Cohen, Amos ; Magen-Nativ, Hila ; Cavo, Michele ; Larocca, Alessandra ; Takezako, Naoki ; Suzuki, Kenshi ; Kosugi, Hiroshi ; Matsumoto, Morio ; Iida, Shinsuke ; Ishikawa, Takayuki ; Kondo, Yukio ; Sunami, Kazutaka ; Ando, Kiyoshi ; Teshima, Takanori ; Chou, Takaaki ; Iwasaki, Hiromi ; Miki, Hirokazu ; Matsumura, Itaru ; Onishi, Yasushi ; Izutsu, Koji ; Kizaki, Masahiro ; George, Anupkumar ; Blacklock, Hillary ; Schjesvold, Fredrik ; Waage, Anders ; Nikitin, Evgeniy ; Chagorova, Tatiana ; McDonald, Andrew ; Patel, Moosa ; Oriol Rocafiguera, Albert ; San Miguel Izquierdo, Jesus ; Mateos, Maria ; Streetly, Matthew ; Forsyth, Peter ; Jackson, Graham ; Jenkins, Stephen ; Rifkin, Robert ; Yimer, Habte ; McCroskey, Robert ; Martincic, Danko ; Tarantolo, Stefano ; Larson, Sarah ; Faroun, Yacoub ; Vaughn, Jennifer ; Saylors, Gene ; Fung, Henry ; Stevens, Don ; Coleman, Morton ; Costa, Dennis ; Cross, Scott ; Fanning, Suzanne ; Berges, Daniel Farray ; Harris, Thomas ; Zackon, Ira ; Atanackovic, Djordje ; Oliff, Ira ; Lee, Wes ; Bensinger, William ; Lutzky, Jose ; Baron, Ari ; Kirschner, Eli ; Bharany, Neeraj ; Overton, Lindsay ; Mannem, Siva ; Harroff, Allyson ; Jain, Sharad ; Roque, Tammy ; Yasencha, Christopher K ; Houck, William

The Lancet. Haematology, 2019-09, Vol.6 (9), p.e448-e458 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
Material Type:
Artigo 		Adicionar ao Meu Espaço

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation

Maio, Michele ; Carlino, Matteo S. ; Joshua, Anthony M. ; McWhirter, Elaine ; Ribas, Antoni ; Ascierto, Paolo A. ; Miller, Wilson H. ; Butler, Marcus O. ; Ferrucci, Pier Francesco ; Zielinski, Robert R. ; Del Vecchio, Michele ; Gasal, Eduard ; Ghori, Razi ; Diede, Scott J. ; Croydon, Elizabeth ; Hamid, Omid

European journal of cancer (1990), 2022-01, Vol.160, p.1-11 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

Woyach, Jennifer A ; Stephens, Deborah M ; Flinn, Ian W ; Bhat, Seema A ; Savage, Ronald E ; Chai, Feng ; Eathiraj, Sudharshan ; Reiff, Sean D ; Muhowski, Elizabeth M ; Granlund, Lindsey ; Szuszkiewicz, Lyndsey ; Wang, Wayne ; Schwartz, Brian ; Ghori, Razi ; Farooqui, Mohammed Z H ; Byrd, John C

Cancer discovery, 2024-01, Vol.14 (1), p.66-75

United States

Texto completo disponível

Citações Citado por
10
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Takezako, Naoki ; Kosugi, Hiroshi ; Matsumoto, Morio ; Iida, Shinsuke ; Ishikawa, Takayuki ; Kondo, Yukio ; Ando, Kiyoshi ; Miki, Hirokazu ; Matsumura, Itaru ; Sunami, Kazutaka ; Teshima, Takanori ; Iwasaki, Hiromi ; Onishi, Yasushi ; Kizaki, Masahiro ; Izutsu, Koji ; Maruyama, Dai ; Tobinai, Kensei ; Ghori, Razi ; Farooqui, Mohammed ; Liao, Jason ; Marinello, Patricia ; Matsuda, Kenji ; Koh, Yasuhiro ; Shimamoto, Takashi ; Suzuki, Kenshi

International journal of hematology, 2020-11, Vol.112 (5), p.640-649 [Periódico revisado por pares]

Singapore: Springer Singapore

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (10)

Data de Publicação 

De até
Refinar
  1. Antes de2019  (1)
  2. 2019Até2019  (5)
  3. 2020Até2020  (3)
  4. 2021Até2022  (2)
  5. Após 2022  (1)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.